pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

centrexion-therapeutics PRESS RELEASE ARCHIVE

Oct 29, 2020

Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors

Oct 29, 2020

Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors

Dec 3, 2019

Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975

Dec 3, 2019

Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975

Nov 8, 2019

Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly

Nov 8, 2019

Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly

Sep 17, 2019

Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain

Sep 17, 2019

Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain

Sep 4, 2019

CORRECTION - Centrexion Therapeutics

Sep 4, 2019

CORRECTION - Centrexion Therapeutics

Jul 18, 2019

Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration Techniques

Jul 18, 2019

Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration Techniques

Jun 11, 2019

Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology

Jun 5, 2019

Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain

Jun 5, 2019

Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain

May 28, 2019

Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics

Apr 29, 2019

Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference and Osteoarthritis Research Society International 2019 World Congress

Apr 29, 2019

Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference and Osteoarthritis Research Society International 2019 World Congress

Mar 27, 2019

Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis and Rheumatology

Mar 7, 2019

Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting

Dec 5, 2018

Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Oct 16, 2018

Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting

Sep 24, 2018

Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer

Sep 6, 2018

Centrexion Therapeutics Announces CNTX-4975 Data Presentation at PAINWeek 2018 National Conference

Aug 15, 2018

Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors

Jul 30, 2018

Centrexion Therapeutics Appoints Financial Executive Nick Harvey as Chief Financial Officer

Jun 26, 2018

Centrexion Therapeutics Appoints Veteran Healthcare Innovator Joseph R. Swedish to its Board of Directors

Jun 18, 2018

Centrexion Therapeutics Selects Skyland Analytics' Skyland PIMS™ Software as their Data Repository for Manufacturing and Quality Compliance

Apr 19, 2018

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

Mar 1, 2018

Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting

Feb 21, 2018

Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Jan 16, 2018

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain

Jan 5, 2018

Centrexion Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

Jan 2, 2018

Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018

Oct 30, 2017

Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017

Sep 26, 2017

Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatments at the 11th Annual Pain and Migraine Therapeutics Summit

Aug 29, 2017

Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017

Jul 20, 2017

Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting

Jul 18, 2017

Centrexion Therapeutics Provides Updates and Advancements for Pipeline of Chronic Pain Treatments

Jun 26, 2017

Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors

Jun 13, 2017

Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

Jun 7, 2017

Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology (EULAR 2017)

Jun 1, 2017

Centrexion Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

May 25, 2017

Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatology’s 2017 Annual Congress

May 10, 2017

Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting

Mar 23, 2017

Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA

Mar 16, 2017

Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting

Feb 9, 2017

Centrexion Therapeutics to Present at the 19th Annual BIO CEO and Investor Conference

Dec 13, 2016

Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Nov 15, 2016

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s Neuroma

Oct 19, 2016

BioXcel and Centrexion Therapeutics Further Advance Big Data Innovation Lab Collaboration in Chronic Pain

Mar 30, 2016

Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim

Google Analytics Alternative